Evidence for an inhibitory gabergic control of the meso-limbic dopamine neurons: possibility of improving treatment of schizophrenia by combined treatment with neuroleptics and gabergic drugs.
Changes in dopamine (DA) turnover have been studied in rats after treatment with pimozide and/or gabergic drugs such as beta-(p-chlorophenyl)-GABA and aminooxyacetic acid using the tyrosine-hydroxylase inhibitor alpha-methyltyrosine and methylester (H44/68). The changes in DA levels were determined by quantitative microfluorimetrical analysis of the fluorescence in various DA terminal systems. Beta-(p-chlorophenyl)-GABA (5--20 mg/kg) and aminooxyacetic acid (25 mg/kg) counteracted the pimozide (1 mg/kg) induced increase in DA turnover in subcortical and cortical limbic regions but not in the caput of the caudatus. These findings indicate the existence of a strong and preferential inhibitory gabergic control of the mesolimbic DA neurons and offer the possibility of improving the treatment of schizophrenia provided that limbic DA receptors are involved in this disease. If so, lesions of gabergic pathways may exist in the schizophrenic brain.
D000613:Aminobutyrates / Q000502:physiology*; D000625:Aminooxyacetic Acid / Q000494:pharmacology; D000818:Animals; D003864:Depression, Chemical; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D008032:Limbic System / Q000502:physiology*; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology; D009474:Neurons / Q000378:metabolism*; D010868:Pimozide / Q000494:pharmacology; D051381:Rats; D013268:Stimulation, Chemical; D014149:Tranquilizing Agents / Q000494:pharmacology*; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology*
D000613:Aminobutyrates; D008781:Methyltyrosines; D014149:Tranquilizing Agents; D000625:Aminooxyacetic Acid; D010868:Pimozide; D005680:gamma-Aminobutyric Acid; D004298:Dopamine